Clinical trial · Interventional
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
A Phase 1 Dose-Escalation Study to Evaluate the Safety and Tolerability of HGS1029 (AEG40826-2HCl) in Patients With Advanced Solid Tumors
NCT00708006CI-TRIAL-00012596completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HGS1029 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- HGS1029
- interventionNames
- Drug: HGS1029
Primary outcomes (1)
- measure
- To assess the safety and dose-limiting toxicity of HGS1029 administered weekly X 3, repeated every 4 weeks
- timeFrame
- throughout the study
Secondary outcomes (1)
- measure
- Determination of pharmacokinetic profile; evaluation of biomarkers; evaluation of possible anti-tumor activity
- timeFrame
- throughout the study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed advanced solid malignancy * Life expectancy of at least 3 months * Age 18 years or older * Acceptable liver function * Acceptable renal function * Acceptable hematologic status Exclusion Criteria: * Received investigational (not yet approved by a regulatory authority)agent within 4 weeks before enrollment. * Received non-investigational agent within 3 weeks before enrollment. * Progressive CNS involvement including the need of corticosteroids * Pregnant or breast-feeding women * Active, uncontrolled bacterial, viral, or fungal infections within 2 weeks of Cycle 1 Day 1 * Known HIV infection
References
Publications (0)
Data not yet available
No reference posted for this study.